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Methods 
Cell lines
MCF7 cell lines were used in this study as a model for ER-
positive breast cancer. Cells were stably transfected to express 
full length cyclin E (EL), LMW-E (T1), or empty vector (4.0) and 
were grown in the presence and absence of estrogen for different 
lengths of time. MDA-MB-231 cells were used as a model for 
triple negative breast cancer (TNBC). These cells were used as a 
negative control for MCF7 ER-positive breast cancer cells.
Hypothesis
We hypothesize that cell cycle inhibitory drugs affect FL and 
LMW-E expressing cells differentially and are dependent on the 
presence of estrogen (E2). 
Results 
Discussion
The data suggest a unique mechanism that differentiates cells 
that express FL-E in E2 containing and E2-deprived media. CDK 
inhibitors fail to specifically inhibit growth of T1-expressing 
MCF7 cells in both E2 media and E2-deprived media. However, 
a CDK1/CDK2 inhibitor specifically inhibits T1-expressing MCF7 
cells in E2-media. Efficacy of this drug in E2 media, alongside 
fundamental changes shown between E2-deprivation and E2-
growth suggests that combination with endocrine therapy may 
be most effective to inhibit growth of these cells. Further studies 
are needed to solidify the mechanism in which cell cycle 
proteins such as PLK1, AURKA, and ERα are regulated in 
different estrogen conditions.
Background
Cyclin E is an important cell cycle regulator controlling the G1/S 
checkpoint. In many cancer types, cyclin E overexpression causes 
dysregulation of the G1/S checkpoint and cell cycle progression1,2. 
Low molecular weight cyclin E (LMW-E) has been associated with 
breast cancer tumorigenesis, genomic instability, and resistance to 
aromatase inhibitors3,4. No approved therapeutic agents exist to 
target ER-positive breast cancer patients that overexpress LMW-
E5. The purpose of this research is to 1) study the underlying 
mechanism in which ER-positive breast cancer cells 
overexpressing LMW-E become resistant to endocrine therapy and 
2) test the efficacy of various cell cycle inhibitors on full length (FL) 
and LMW-E expressing ER-positive breast cancer cell growth.
Results (continued) Results (continued) 
Figure 2. MCF7 cells expressing FL-E, LMW-E, or empty vector were 
grown for 14 days with various CDK inhibitors in the presence and 
absence of 1 nM E2. 
Dose response assays
MCF7 cells expressing 4.0, EL, and T1 were cultured in 96-well 
plates for 14 days with various cell cycle drugs in IMEM cell 
media without E2 or with 1 nM E2. Media and drug were 
refreshed every other day before cell confluency was measured 
using an IncuCyte ©. After 14 days, cell confluency was 
measured using a crystal violet stain.
Immunoblot assays
1x106 cells were sonicated and centrifuged and protein 
concentration was measured via BSA assay. Samples were run 
on SDS-PAGE gels and then transferred to nitrocellulose 
membranes overnight at 4℃. The membranes were blocked for in 
5% BSA and incubated with indicated primary antibody overnight 
at 4℃. Membranes were then incubated with anti-mouse or anti-
rabbit secondary antibody. Films were developed using the 
Renaissance chemiluminescence system.
Figure 3. MCF7 cells expressing FL-E, LMW-E, or empty vector were 
treated for 20 days with a CDK1/CDK2 inhibitor in the presence and 
absence of 1 nM E2. 
Figure 4. Western blot analysis of 4.0, EL, and T1 MCF7 cells grown in 
the presence and absence of 1 nM PLK1i (Vol) and E2 for 48 hours. 
ERα, PLK1, Cyclin E (FL-E and LMW-E), and Aurora Kinase A were 
measured.
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Figure 1. (A) Cell images of 4.0, EL, and T1 MCF7 cells cultured in the 
presence or absence of E2 for 13 days. (B) Cell cycle flow cytometry of 
4.0, EL, and T1 MCF7 cells grown in the presence and absence of 1 nM 
E2 for 48 hours. Cell cycle phase was quantified using FlowJo and 
analyzed with GraphPad Prism. (C) Western blot analysis of 4.0, EL, 
and T1 MCF7 cells grown in the presence and absence of 1 nM E2 for 




Effect of E2 deprivation on cell growth
Differences in cell growth, cell cycle status, and protein 
expression were observed for 4.0 and EL cells grown in E2 
media compared to E2-deprived media (Fig. 1). These 
differences were seen at one week (Fig. 1A), 48 hours (Fig. 1B) 
and 24 hours of E2 deprivation (Fig. 1C). No significant 
differences were observed in T1 cells. 
Dose response assay of various cell cycle inhibitors
Treatment of MCF7 cells with 4 novel CDK inhibitors showed no 
specificity for T1 cells in either E2 media or E2-deprived 
conditions (Fig. 2). An inhibitor of CDK1/CDK2 was found to 
specifically target T1 cells in E2 media. Drug specificity was lost 
in E2 deprived media (Fig. 3). Overall, data shows altered 
specificity to T1 over EL and 4.0 amongst the various tested 
CDK inhibitors. 
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A potent PLK1 inhibitor, Volasertib, has recently been shown in 
our lab to inhibit 4.0, EL and T1 cells growth at 1nM. Western 
blot analysis of cells treated for 48hr with Volasertib at 1nM 
revealed differential patterns of ERα and Cyclin E expression 
(Fig. 4). 
Despite the changes in cell growth, T1 exhibited no changes in 
protein expression
